Adedayo Mokuolu, MD
Gastroenterology · Henderson, NVNPI 1467485409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 488 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 32.9% of the total.
Across 488 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$966
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$689
- Gilead$369
- Sanofi$319
- plus $2K from 25 others
What the payments were for
- Food & beverage$7,70096%
- Education$3084%
- Gifts$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 167 | $2,655 |
| Johnson & Johnson(2 entities) | 83 | $1,351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $966 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $689 |
| Gilead | 25 | $369 |
| Sanofi | 17 | $319 |
| Redhill Biopharma Inc. | 7 | $145 |
| Ferring Pharmaceuticals Inc. | 8 | $145 |
| Bristol Myers Squibb | 8 | $145 |
| Ironwood Pharmaceuticals, Inc | 7 | $128 |
| Lilly USA, LLC | 5 | $121 |
| Pfizer | 6 | $119 |
| Regeneron Healthcare Solutions, Inc. | 5 | $110 |
| Intercept Pharmaceuticals, Inc. | 6 | $98 |
| Braintree Laboratories, Inc. | 4 | $97 |
| Merck | 6 | $91 |
| UCB, Inc. | 4 | $89 |
| Alfasigma USA, Inc. | 3 | $59 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Ardelyx, Inc. | 2 | $50 |
| Endogastric Solutions, Inc | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Boston Scientific | 1 | $34 |
| Intra-sana Laboratories | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Sandoz | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Shionogi Inc | 1 | $13 |
How this compares
$8,061 in reported general payments places this provider in the 75th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $112,856 |
| LinzessLinaclotide | 109 | $91,386 |
| CreonLipase/Protease/Amylase | 34 | $90,516 |
| ZenpepLipase/Protease/Amylase | 19 | $72,243 |
| XifaxanRifaximin | 15 | $47,453 |
| VemlidyTenofovir Alafenamide | 27 | $44,076 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 203 | $34,817 |
| Mesalamine | 68 | $28,115 |
| Dexlansoprazole DrDexlansoprazole | 76 | $17,252 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 261 | $16,332 |
| TrulancePlecanatide | 12 | $11,146 |
| Pantoprazole Sodium | 763 | $7,787 |
| Sucralfate | 144 | $7,342 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 50 | $7,195 |
| Lubiprostone | 70 | $6,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,655 | $181,902143 claims |
| UCB, Inc.Cimzia (2 Pack) | $89 | $112,85617 claims |
| Aimmune Therapeutics, Inc.Zenpep | $16 | $72,24319 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $689 | $65,79477 claims |
| GileadVemlidy | $369 | $44,07627 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $145 | $34,817203 claims |
| SandozLansoprazole | $19 | $54032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Henderson
- Rajat SoodHenderson$258K
- Robert YehHenderson$16K
- Muthena MakladHenderson$10K
- Carmelo HerreroHenderson$9K
- Jonathan RickerHenderson$8K
- Arumugam SivakumarHenderson$7K
- Bipin SaudHenderson$6K
- Christian StoneLas Vegas$1.1M
- Yasser SaloumNorth Las Vegas$49K
- James HanLas Vegas$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.